Access the full text.
Sign up today, get DeepDyve free for 14 days.
It was by chance that I became involved in 1946 in the clinical evaluation of antihypertensive agents. After World War II, I had returned to Boston to complete my residency training in internal medicine and to work in hemodynamics research with Robert Wilkins at the Massachusetts Memorial Hospital. Surgical sympathectomy was then the popular method for treating hypertension and Dr. Wilkins was involved with Reginald Smithwick in assessing the cardiovascular and circulatory changes associated with this operative procedure. However, Dr. Wilkins and Chester Keefer had been asked by James Shannon, who was then director of the Squibb Institute for Medical Research, to work with the Institute in exploring the possibility of developing a successful chemotherapy for hypertension. The clinical evaluation of any drugs that might emerge in this project was assigned to me working under the direction of Dr. Wilkins. The first drug tested was an outgrowth of the World
JAMA – American Medical Association
Published: Nov 15, 1971
Read and print from thousands of top scholarly journals.
Already have an account? Log in
Bookmark this article. You can see your Bookmarks on your DeepDyve Library.
To save an article, log in first, or sign up for a DeepDyve account if you don’t already have one.
Copy and paste the desired citation format or use the link below to download a file formatted for EndNote
Access the full text.
Sign up today, get DeepDyve free for 14 days.
All DeepDyve websites use cookies to improve your online experience. They were placed on your computer when you launched this website. You can change your cookie settings through your browser.